MCID: RFR009
MIFTS: 31

Refractory Cytopenia with Multilineage Dysplasia

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Refractory Cytopenia with Multilineage Dysplasia

MalaCards integrated aliases for Refractory Cytopenia with Multilineage Dysplasia:

Name: Refractory Cytopenia with Multilineage Dysplasia 58

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 D46.7
UMLS via Orphanet 72 C0796466
Orphanet 58 ORPHA86836

Summaries for Refractory Cytopenia with Multilineage Dysplasia

MalaCards based summary : Refractory Cytopenia with Multilineage Dysplasia is related to refractory anemia and myelodysplastic syndrome. An important gene associated with Refractory Cytopenia with Multilineage Dysplasia is SF3B1 (Splicing Factor 3b Subunit 1), and among its related pathways/superpathways is HIF-1-alpha transcription factor network. The drugs Idarubicin and Decitabine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are HIV Rev nuclear localization and hematopoietic system

Related Diseases for Refractory Cytopenia with Multilineage Dysplasia

Diseases related to Refractory Cytopenia with Multilineage Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 45, show less)
# Related Disease Score Top Affiliating Genes
1 refractory anemia 30.8 TET2 SF3B1 ASXL1
2 myelodysplastic syndrome 30.7 U2AF1 TET2 SF3B1 SETBP1 GATA2 ENG
3 autosomal recessive pyridoxine-refractory sideroblastic anemia 2 30.4 TET2 SF3B1
4 myeloid leukemia 29.9 U2AF1 TET2 GATA2 ASXL1
5 essential thrombocythemia 29.7 U2AF1 TET2 ASXL1
6 leukemia, acute myeloid 29.1 U2AF1 TET2 SF3B1 SETBP1 GATA2 ASXL1
7 chronic myelomonocytic leukemia 28.7 U2AF1 TET2 SF3B1 SETBP1 GATA2 ASXL1
8 chromosome 5q deletion syndrome 10.5
9 hypercholesterolemia, familial, 1 10.2
10 membranous nephropathy 10.2
11 nephrotic syndrome 10.2
12 neutropenia 10.2
13 thrombocytopenia 10.2
14 glomerulonephritis 10.2
15 hypereosinophilic syndrome 10.2
16 chromosomal triplication 10.2
17 refractory anemia with excess blasts in transformation 10.2
18 tetrasomy 5p 10.2
19 systemic mastocytosis with associated hematologic neoplasm 10.1 TET2 ASXL1
20 myelophthisic anemia 10.0 U2AF1 ASXL1
21 neutrophilia, hereditary 9.9 U2AF1 SETBP1
22 mixed phenotype acute leukemia 9.8 U2AF1 SETBP1
23 patau syndrome 9.8 U2AF1 ASXL1
24 childhood acute myeloid leukemia 9.8 TET2 SETBP1 ASXL1
25 extracutaneous mastocytoma 9.8 U2AF1 TET2 ASXL1
26 sm-ahnmd 9.8 U2AF1 TET2 ASXL1
27 mast cell neoplasm 9.7 U2AF1 ASXL1
28 indolent systemic mastocytosis 9.7 U2AF1 TET2 ASXL1
29 systemic mastocytosis 9.7 U2AF1 TET2 ASXL1
30 chronic eosinophilic leukemia 9.7 U2AF1 TET2 ASXL1
31 aggressive systemic mastocytosis 9.7 U2AF1 TET2 ASXL1
32 thrombocytosis 9.7 U2AF1 TET2 ASXL1
33 bone marrow cancer 9.7 U2AF1 TET2 ASXL1
34 polycythemia vera 9.6 U2AF1 TET2 ASXL1
35 shwachman-diamond syndrome 1 9.6 U2AF1 GATA2
36 leukemia 9.5 U2AF1 TET2 GATA2 ASXL1
37 myelodysplastic/myeloproliferative neoplasm 9.5 U2AF1 TET2 SETBP1 ASXL1
38 chronic neutrophilic leukemia 9.5 U2AF1 TET2 SETBP1 ASXL1
39 atypical chronic myeloid leukemia 9.5 U2AF1 TET2 SETBP1 ASXL1
40 chronic leukemia 9.5 U2AF1 TET2 SETBP1 ASXL1
41 juvenile myelomonocytic leukemia 9.4 U2AF1 TET2 SETBP1 ASXL1
42 aplastic anemia 9.4 U2AF1 TET2 GATA2 ASXL1
43 melanoma, uveal 9.3 U2AF1 SF3B1 ENG ASXL1
44 leukemia, chronic myeloid 9.0 U2AF1 SETBP1 GATA2 ENG ASXL1
45 myelofibrosis 8.7 U2AF1 TET2 SETBP1 GATA2 ENG ASXL1

Graphical network of the top 20 diseases related to Refractory Cytopenia with Multilineage Dysplasia:



Diseases related to Refractory Cytopenia with Multilineage Dysplasia

Symptoms & Phenotypes for Refractory Cytopenia with Multilineage Dysplasia

GenomeRNAi Phenotypes related to Refractory Cytopenia with Multilineage Dysplasia according to GeneCards Suite gene sharing:

26 (showing 1, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 HIV Rev nuclear localization GR00247-A-3 8.62 SF3B1 U2AF1

MGI Mouse Phenotypes related to Refractory Cytopenia with Multilineage Dysplasia:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.5 ASXL1 ENG GATA2 IDS PRDX2 SF3B1
2 homeostasis/metabolism MP:0005376 9.17 ASXL1 ENG GATA2 IDS PRDX2 SETBP1

Drugs & Therapeutics for Refractory Cytopenia with Multilineage Dysplasia

Drugs for Refractory Cytopenia with Multilineage Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 92, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Idarubicin Approved Phase 3 58957-92-9 42890
2
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
3
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
4
Etanercept Approved, Investigational Phase 2 185243-69-0
5
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
6
Bexarotene Approved, Investigational Phase 2 153559-49-0 82146
7
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
8
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
9
Etoposide Approved Phase 2 33419-42-0 36462
10
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
11
Melphalan Approved Phase 2 148-82-3 460612 4053
12
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
13
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
14
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
15
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
16
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
17
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
18
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
19
Busulfan Approved, Investigational Phase 2 55-98-1 2478
20 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
21
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
22
Darbepoetin alfa Approved, Investigational Phase 2 11096-26-7, 209810-58-2
23
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
24
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
25
leucovorin Approved Phase 2 58-05-9 6006 143
26
Mycophenolic acid Approved Phase 2 24280-93-1 446541
27
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
28
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
29
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
30
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
31
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
32
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
34
Vatalanib Investigational Phase 2 212141-54-3 151194
35 Molgramostim Investigational Phase 2 99283-10-0
36
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
37 Lintuzumab Investigational Phase 2 166089-32-3
38 Vaccines Phase 2
39 Adjuvants, Immunologic Phase 2
40 Freund's Adjuvant Phase 2
41 topoisomerase I inhibitors Phase 2
42 Protein Kinase Inhibitors Phase 2
43 Analgesics, Non-Narcotic Phase 2
44 Analgesics Phase 2
45 Anti-Inflammatory Agents, Non-Steroidal Phase 2
46 Radiation-Protective Agents Phase 2
47 Antiviral Agents Phase 2
48 Etoposide phosphate Phase 2
49 Gastrointestinal Agents Phase 2
50 Immunologic Factors Phase 2
51 Immunosuppressive Agents Phase 2
52 Antirheumatic Agents Phase 2
53 Anti-Inflammatory Agents Phase 2
54 Antilymphocyte Serum Phase 2
55 Alkylating Agents Phase 2
56 Micronutrients Phase 2
57 Vitamins Phase 2
58 Trace Elements Phase 2
59 Hormones Phase 2
60 Nutrients Phase 2
61 Calcium, Dietary Phase 2
62 Calciferol Phase 2
63 Protective Agents Phase 2
64 Anti-Infective Agents Phase 2
65 Antimetabolites Phase 2
66 Antibiotics, Antitubercular Phase 2
67 Anti-Bacterial Agents Phase 2
68 Methylprednisolone Acetate Phase 2
69 Mitogens Phase 2
70 Epoetin alfa Phase 2 113427-24-0
71 Antineoplastic Agents, Immunological Phase 2
72 Vitamin B Complex Phase 2
73 Folic Acid Antagonists Phase 2
74 Folate Phase 2
75 Calcineurin Inhibitors Phase 2
76 Dermatologic Agents Phase 2
77 Vitamin B9 Phase 2
78 Antitubercular Agents Phase 2
79 Antifungal Agents Phase 2
80 Immunoglobulins Phase 2
81 Antibodies Phase 2
82 Antidotes Phase 2
83 Antiemetics Phase 2
84 Cyclosporins Phase 2
85 Hormone Antagonists Phase 2
86 glucocorticoids Phase 2
87 Neuroprotective Agents Phase 2
88 Antibodies, Monoclonal Phase 2
89
Calcium Nutraceutical Phase 2 7440-70-2 271
90 Tissue Plasminogen Activator Phase 1
91
Pancrelipase Approved, Investigational 53608-75-6
92 pancreatin

Interventional clinical trials:

(showing 32, show less)
# Name Status NCT ID Phase Drugs
1 Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (SAML) to MDS of More Acute Than 6 Months Duration Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
2 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
3 Phase 2 Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA 51 VG Adjuvant and Administered With GM-CSF in Low Risk and Intermediate-1 MDS Unknown status NCT00513578 Phase 2
4 A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS) Completed NCT00003675 Phase 2 topotecan hydrochloride
5 A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS) Completed NCT00072475 Phase 2 vatalanib
6 Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc Completed NCT00005853 Phase 2
7 Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) After T-Lymphocyte Depleted Allogeneic BMT for Myelodysplastic Syndromes Completed NCT00003961 Phase 2
8 A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML Completed NCT00425477 Phase 2 bexarotene
9 A Phase II Study Of Amifostine In Children With Myelodysplastic Syndrome Completed NCT00098683 Phase 2 amifostine trihydrate
10 HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY Completed NCT00731328 Phase 2
11 Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors Completed NCT00005622 Phase 2 cyclophosphamide
12 A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies Completed NCT00014469 Phase 2 busulfan;melphalan;methotrexate;tacrolimus
13 Hematopoietic Stem Cell Transplantation Using Bone Marrow Or Peripheral Blood Stem Cells From Matched, Unrelated, Volunteer Donors Completed NCT00054327 Phase 2 busulfan;cyclophosphamide;cytarabine;Etoposide
14 A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
15 A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
16 Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
17 Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan Completed NCT00619645 Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil
18 Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen Completed NCT00365287 Phase 1, Phase 2 anti-thymocyte globulin;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
19 Phase II Trial of Arsenic Trioxide and Dose-Escalated Cholecalciferol in Myelodysplastic Syndrome Terminated NCT00104806 Phase 2 arsenic trioxide
20 Combination of Azacitadine and Hematopoietic Growth Factors for Myelodysplastic Syndrome Terminated NCT00398047 Phase 2 Azacitadine and Hematopoietic Growth Factors
21 Phase II Study of 5-azacytidine and Lintuzumab in Myelodysplastic Syndromes (MDS) Terminated NCT00997243 Phase 2 5-azacytidine
22 T-Cell Depletion for Graft-Versus-Host Disease (GVHD) Prevention in High Risk Matched and Mismatched Allogeneic Bone Marrow Transplantation Terminated NCT00005641 Phase 2 busulfan;cyclophosphamide;cyclosporine;leucovorin calcium;methotrexate;methylprednisolone
23 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
24 A Phase I Trial Of VNP40101M, A Novel Alkylating Agent, For Patients With Hematologic Malignancies Completed NCT00049686 Phase 1 laromustine
25 A Phase I Open-Label, Safety Study of Haploidentical Bone Marrow Transplantation (BMT) After Ex Vivo Treatment of Bone Marrow With Anti-B7.1 and Anti-B7.2 Antibodies Completed NCT00005988 Phase 1 cyclophosphamide;cyclosporine;leucovorin calcium;methotrexate;methylprednisolone
26 Nonmyeloablative Bone Marrow Transplants in Hematologic Malignancies: Dose Finding Study for Post-Transplant Immunosuppression Completed NCT00255710 Phase 1 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
27 Phase I Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) in Patients With Refractory Hematologic Malignancies/Bone Marrow Disorders Terminated NCT00004058 Phase 1 tetradecanoylphorbol acetate
28 Non-Myeloablative Chemotherapy Followed by Unrelated Allogeneic Stem Cell Transplantation in Patients With Advanced Hematologic Malignancies: A Pilot Study Withdrawn NCT00004114 Phase 1 cyclophosphamide;cytarabine;fludarabine phosphate
29 Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC) Unknown status NCT00898118
30 TCR Vbeta Repertoire and PNH Clones in Children With Refractory Cytopenia (RC). An Open Nonrandomised Multi-Center Prospective Study Completed NCT00499070
31 A Cyclophosphamide/Fludarabine/Total Body Irradiation Preparative Regimen for Patients With Hematological Malignancy Receiving Unrelated Donor Umbilical Cord Blood Transplantation Completed NCT00290641 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
32 K562/GM-CSF Vaccination in Patients With Myelodysplastic Syndrome Terminated NCT00361296 Early Phase 1

Search NIH Clinical Center for Refractory Cytopenia with Multilineage Dysplasia

Genetic Tests for Refractory Cytopenia with Multilineage Dysplasia

Anatomical Context for Refractory Cytopenia with Multilineage Dysplasia

MalaCards organs/tissues related to Refractory Cytopenia with Multilineage Dysplasia:

40
Bone, Bone Marrow, Myeloid, T Cells, Lung, Skin, B Cells

Publications for Refractory Cytopenia with Multilineage Dysplasia

Articles related to Refractory Cytopenia with Multilineage Dysplasia:

(showing 164, show less)
# Title Authors PMID Year
1
Myelodysplastic syndromes in a pediatric patient with Cri du Chat syndrome with a ring chromosome 5. 61
32519173 2020
2
SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia. 61
32037286 2020
3
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. 61
32027747 2020
4
Epigenetic changes in FOXO3 and CHEK2 genes and their correlation with clinicopathological findings in myelodysplastic syndromes. 61
32217071 2020
5
Effect of Qinghuang Powder () Combined with Bupi Yishen Decoction () in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation. 61
29500545 2019
6
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. 61
30287621 2019
7
Gender disparity in the survival of patients with primary myelodysplastic syndrome. 61
30854142 2019
8
[Successful cord blood transplantation for myelodysplastic syndrome with Behçet disease-like refractory stomatitis and multiple ileocecal ulcerations]. 61
31695004 2019
9
Methylation level of Rap1GAP and the clinical significance in MDS. 61
30546468 2018
10
Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations. 61
30502853 2018
11
Gastric carcinoma subsequent to myelodysplastic syndrome with t (1; 19) chromosome translocation: A rare case report and its potential mechanisms. 61
30045276 2018
12
[Relationship between clinical features and somatic gene mutations in myelodysplastic syndrome]. 61
29415943 2018
13
[MonoMAC syndrome patient developing myelodysplastic syndrome following persistent EBV infection]. 61
29618691 2018
14
DNA repair gene expressions are related to bone marrow cellularity in myelodysplastic syndrome. 61
28554891 2017
15
TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. 61
28687222 2017
16
Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. 61
28705782 2017
17
Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes. 61
28300669 2017
18
Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. 61
28822917 2017
19
p53 protein expression in patients with myelodysplasia treated with allogeneic bone marrow transplantation. 61
28588781 2017
20
Hospital-Based Case-Control Study of MDS Subtypes and Benzene Exposure in Shanghai. 61
28146040 2017
21
Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group. 61
27699872 2017
22
Myelodysplastic Syndrome Developing Presacral Extramedullary Hematopoiesis with Atypical MRI Findings. 61
28502939 2017
23
Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. 61
27391606 2016
24
Monitoring of the Clonal Fraction by Fluorescence In Situ Hybridization in Myelodysplastic Syndrome: Comparison With International Working Group Treatment Response Criteria. 61
27232348 2016
25
[Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome: a case report]. 61
26744238 2016
26
Spectrum of the WHO Classification De Novo Myelodysplastic Syndrome: Experience from Southern Pakistan. 61
27039723 2016
27
[Establishment of Primary Adult MDS Nested Case-Control Study Cohort and Study of Risk Factors Associated with MDS Evolution to Leukemia]. 61
26708886 2015
28
Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine. 61
26273061 2015
29
In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time. 61
25960152 2015
30
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. 61
25957392 2015
31
[Cold autoimmune hemolytic anemia complicated with relapsed myelodysplastic syndrome after allogeneic hematopoietic cell transplantation]. 61
25971272 2015
32
Tea consumption reduces the risk of de novo myelodysplastic syndromes. 61
25529769 2015
33
A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon. 61
27069756 2015
34
Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome. 61
23634876 2015
35
Peripheral blood mononuclear cell proteome changes in patients with myelodysplastic syndrome. 61
25969835 2015
36
Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor. 61
25709889 2015
37
[Treatment of myelodysplastic syndrome by hematopoietic stem cell transplantation combined with Chinese medical syndrome typing: a clinical study]. 61
25790675 2015
38
Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing. 61
26637696 2015
39
Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups. 61
26448929 2015
40
Refractory thrombocytopenia and neutropenia: a diagnostic challenge. 61
25745545 2015
41
New insights on iron study in myelodysplasia. 61
25541657 2014
42
CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes. 61
25199050 2014
43
Successful treatment of myelodysplastic syndrome and chronic hepatitis C using combined peginterferon-α-2b and ribavirin therapy. 61
24224981 2014
44
Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia. 61
24862795 2014
45
Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. 61
24850867 2014
46
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. 61
24440648 2014
47
Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. 61
24388662 2014
48
Refractory anemia with ring sideroblasts. 61
24507814 2013
49
Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up. 61
24260074 2013
50
Case report: A novel TET2 mutation in a patient with refractory cytopenia with multilineage dysplasia. 61
24301955 2013
51
[Relationship between polymorphisms of tumor necrosis factor alpha gene and primary myelodysplastic syndromes]. 61
24171962 2013
52
[Association between multiple myeloma and acute myeloid leukemia secondary to myelodysplastic syndrome]. 61
24113443 2013
53
Membranous glomerulonephritis in a patient with myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia. 61
26877929 2013
54
Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure. 61
23403320 2013
55
[Clinical features of cytopenia with bone marrow hypoplasia in children: an analysis of 100 cases]. 61
23791060 2013
56
Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome. 61
23411464 2013
57
Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome. 61
23566303 2013
58
[Myelodysplastic syndrome classification]. 61
23587576 2013
59
[Detection of chromosome abnormalities in myelodysplastic syndromes with interval fluorescence in situ hybridization]. 61
23484703 2013
60
Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. 61
22948274 2013
61
Alteration in endoglin-related angiogenesis in refractory cytopenia with multilineage dysplasia. 61
23341958 2013
62
Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS). 61
22983749 2013
63
Two copies of isochromosome 5p in refractory cytopenia with multilineage dysplasia: A case report. 61
24371769 2013
64
Hypocupremia associated cytopenia and myelopathy: a national retrospective review. 61
23034053 2013
65
H3K27me3 inhibitor: a potential new therapy for cytogenetically normal refractory cytopenia with multilineage dysplasia. 61
24303562 2013
66
Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience. 61
22647078 2012
67
Identification of genes underlying different methylation profiles in refractory anemia with excess blast and refractory cytopenia with multilineage dysplasia in myelodysplastic syndrome. 61
23071473 2012
68
5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. 61
22280532 2012
69
Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome. 61
22690734 2012
70
Diagnosis of acquired bone marrow failure syndrome during childhood using the 2008 World Health Organization classification system. 61
22562435 2012
71
Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. 61
22554895 2012
72
Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. 61
22539801 2012
73
Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. 61
22568928 2012
74
The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. 61
22133642 2012
75
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. 61
22211483 2012
76
[Aplastic anemia complicated with ulcerative colitis]. 61
22450583 2012
77
[Sustained remission of blastic plasmacytoid dendritic cell neoplasm with ABVD chemotherapy]. 61
22450587 2012
78
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. 61
22033490 2012
79
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. 61
22096241 2012
80
Myelodysplastic Syndrome with t(1;7) Associated with Marked Dysmegakarypoiesis & Severe Thrombocytopenia: A Case Report and Review of the Literature. 61
22937318 2012
81
Disseminated adenovirus disease in immunocompromised patient successfully treated with oral ribavirin: a case report. 61
21964861 2011
82
A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia. 61
22131879 2011
83
Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. 61
22089606 2011
84
[Acute lung injury in a patient with concurrent diffuse large B-cell lymphoma and myelodysplastic syndrome]. 61
21996978 2011
85
Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. 61
21975265 2011
86
[Evolution of a refractory cytopenia with multilineage dysplasia and ring sideroblasts to chronic myelomonocytic leukemia]. 61
22076892 2011
87
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. 61
21659356 2011
88
Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia. 61
21757602 2011
89
Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. 61
21397943 2011
90
Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. 61
21067809 2011
91
[Cytogenetic peculiarity of chromosomal abnormalities in myelodisplastic syndromes in childhood]. 61
22606895 2011
92
Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes. 61
21447369 2011
93
Long-term outcome of isolated thrombocytopenia accompanied by hypocellular marrow. 61
21747886 2011
94
[Expression of CD133 in the bone marrow of patients with myelodysplastic syndrome and its clinical significance]. 61
21602141 2011
95
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. 61
20922525 2011
96
Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study. 61
20591481 2011
97
Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1alpha-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes. 61
20569983 2010
98
Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes. 61
20022110 2010
99
Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. 61
20331464 2010
100
Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study. 61
19921190 2010
101
[Value of imprint in bone marrow morphological examination]. 61
20973233 2010
102
Integrating WHO 2001-2008 criteria for the diagnosis of Myelodysplastic Syndrome (MDS): a case-case analysis of benzene exposure. 61
19941839 2010
103
Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. 61
19719471 2010
104
Derivative (1)t(1;16)(p11;p11.1) in myelodysplastic syndrome: a case report and review of the literature. 61
19963141 2010
105
Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. 61
20368773 2010
106
Pulmonary alveolar proteinosis as a terminal complication in a case of myelodysplastic syndrome with idic(20q-). 61
19955712 2010
107
[Efficiency of cyclosporin A therapy in patients with myelodysplastic syndrome]. 61
20873246 2010
108
Myelodysplastic syndromes/neoplasms: recent classification system based on World Health Organization Classification of Tumors - International Agency for Research on Cancer for Hematopoietic and Lymphoid Tissues. 61
22282696 2010
109
Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: morphologic and cytogenetic characteristics. 61
20023263 2010
110
Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome. 61
18691343 2009
111
Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia. 61
19737310 2009
112
A rare case of an acquired factor VIII inhibitor associated with refractory cytopenia with multilineage dysplasia. 61
20233237 2009
113
[The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification]. 61
19954053 2009
114
Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. 61
19528370 2009
115
JAK2 V617F mutation is associated with 5q- syndrome in Chinese. 61
19562618 2009
116
[Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome]. 61
19953928 2009
117
T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases. 61
19228641 2009
118
Clinical significance of regulatory T cells in patients with myelodysplastic syndrome. 61
19018862 2009
119
Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes. 61
19036104 2009
120
[Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts]. 61
19563026 2009
121
Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. 61
19135940 2009
122
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). 61
19025972 2009
123
Co-existent de novo myelodysplastic syndrome and T-cell non-Hodgkin lymphoma: a common origin or not? 61
19215701 2009
124
Inverted duplication dup(1)(q32q21) as sole aberration in lymphoid and myeloid malignancies. 61
19100515 2009
125
Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia. 61
18284457 2008
126
[WHO classification and cytogenetic analysis of 435 cases with myelodysplastic syndrome]. 61
19040061 2008
127
[Scoring analysis on prognosis of 63 patients with melodysplastic syndrome]. 61
18426654 2008
128
[Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome]. 61
18247301 2008
129
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. 61
17971483 2008
130
A complex chromosome 3 rearrangement not affecting RPN1, EVI1/MDS1 genes in a patient with an atypical refractory cytopenia with multilineage dysplasia. 61
17960379 2008
131
Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. 61
17412418 2008
132
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. 61
17634407 2007
133
Refractory cytopenia with multilineage dysplasia and eosinophilia. 61
17315218 2007
134
Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. 61
17268513 2007
135
Laparoscopic splenectomy can induce significant improvement in hypoplastic myelodysplastic syndrome. 61
17966448 2007
136
Unusual complex hyperdiploid karyotypes in myelodysplastic syndromes. 61
17011983 2006
137
Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis. 61
16715299 2006
138
Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients. 61
16423393 2006
139
Clonal "devolution" in a case of essential thrombocythemia with transformation from refractory cytopenia with multilineage dysplasia to acute myeloid leukemia. 61
16840213 2006
140
Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes. 61
16634964 2006
141
Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. 61
16408206 2006
142
Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome. 61
16451398 2006
143
Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes. 61
16102825 2006
144
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. 61
16270213 2005
145
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. 61
16186598 2005
146
Classification of myeloid neoplasms: a comparative review. 61
16134066 2005
147
The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia. 61
15725470 2005
148
Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study. 61
15725083 2005
149
[Karyotypic and IPSS grouping of primary myelodysplastic syndromes patients: a comparison between FAB- and WHO-classification]. 61
15555265 2004
150
Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. 61
15120930 2004
151
[Unrelated HLA-matched donor marrow transplantation for one case of myelodysplastic syndrome]. 61
15228672 2004
152
[Azathioprine-associated myelodysplastic syndrome with cytogenetic aberrations]. 61
15170581 2004
153
[Refractory anemia (RA) and refractory cytopenia with multilineage dysplasia (RCMD) in WHO classification: comparison between Japanese and German cases]. 61
15168441 2004
154
[Myelodisplasic syndromes diagnosed in a geriatric hospital: morphological profile in 100 patients]. 61
15047472 2004
155
Blastic natural killer-cell lymphoma of the skin associated with myelodysplastic syndrome or myelogenous leukaemia: a coincidence or more? 61
14616384 2003
156
Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia. 61
14506644 2003
157
Donor-cell myelodysplastic syndrome developing 13 years after marrow grafting for aplastic anemia. 61
12699888 2003
158
A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome. 61
12537974 2003
159
Refractory Thrombocytopenia with Multilineage Dysplasia: A Rare Type of Myelodysplastic Syndrome. 61
27265331 2003
160
Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. 61
12592327 2003
161
Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: remission of refractory anemia following mycophenolate mofetil. 61
12483369 2002
162
Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. 61
11698274 2001
163
Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. 61
9573680 1998
164
Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. 61
8558932 1996

Variations for Refractory Cytopenia with Multilineage Dysplasia

Expression for Refractory Cytopenia with Multilineage Dysplasia

Search GEO for disease gene expression data for Refractory Cytopenia with Multilineage Dysplasia.

Pathways for Refractory Cytopenia with Multilineage Dysplasia

Pathways related to Refractory Cytopenia with Multilineage Dysplasia according to GeneCards Suite gene sharing:

(showing 1, show less)
# Super pathways Score Top Affiliating Genes
1 10.44 GATA2 ENG

GO Terms for Refractory Cytopenia with Multilineage Dysplasia

Biological processes related to Refractory Cytopenia with Multilineage Dysplasia according to GeneCards Suite gene sharing:

(showing 5, show less)
# Name GO ID Score Top Affiliating Genes
1 hemopoiesis GO:0030097 9.32 GATA2 ASXL1
2 bone development GO:0060348 9.26 ENG ASXL1
3 negative regulation of fat cell differentiation GO:0045599 9.16 GATA2 ASXL1
4 thymus development GO:0048538 8.96 PRDX2 ASXL1
5 homeostasis of number of cells GO:0048872 8.62 PRDX2 ASXL1

Sources for Refractory Cytopenia with Multilineage Dysplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....